Immunicum AB announced the appointment of Leopold Bertea as Chief Technology Officer, effective as of May 5, 2022. he most recently held the position of Senior Vice President Technical Operations Europe and Member of the Cellectis Executive Committee. With previous senior roles at Novartis, LFB Biotechnologies and LFB's subsidiary CELLforCURE, Sanofi, and Ciba-Geigy, Dr. Bertea brings a total of 27 years biopharmaceutical industry experience to Immunicum.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.456 SEK | +2.01% | -5.98% | -12.81% |
May. 17 | Transcript : Mendus AB, Q1 2024 Earnings Call, May 17, 2024 | |
May. 17 | Mendus AB Announces Board Changes | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.81% | 42.05M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- IMMU Stock
- News Mendus AB
- Immunicum AB Appoints Leopold Bertea as Chief Technology Officer